Health Condition 1: G40- Epilepsy and recurrent seizures
Conditions
Interventions
None listed
Sponsors
AIIMS New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Clinically diagnosed persons with epilepsy (PWE) Subject 18 to 50 years old either male and female Subjects going to start or already on AED (valproate and levetiracetam) monotherapy for not more than 3 months Patient ready to give informed consent
Exclusion criteria
Exclusion criteria: Pregnant or lactating women Associated neurological diseases other than epilepsy Any other active disease (e.g. infectious, psychiatric, disabling chronic diseases) likely to impair metabolic status and physical activity Walking abnormalities including leg injuries, bone fractures, congenital abnormalities Patient on anti-tubercular drugs or any other drugs known to cause interaction with AEDs (e.g. isoniazid, fluoxetine, fluvoxamine, clarithromycin, erythromycin, fluconazole etc.) Patient with significant hepatic and renal impairment that may require dose alteration. Patient refuses to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| changes in metabolic status in persons with epilepsy after 6 months of antiepileptic drug therapyTimepoint: At baseline/enrollment After 6 months of 6 months of antiepileptic drug therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| correlate above changes in metabolic status with serum antiepileptic drug level and physical activity scoreTimepoint: Baseline and 6 months after follow up | — |
Countries
India
Contacts
Public ContactSudhir Chandra Sarangi
AIIMS, New Delhi
Outcome results
None listed